ReviewGastroenterology2015
Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits.
Review in Gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 221 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
221 citing papers in PubMed, 3 syntheses or guidelines pooled it, 462 citations in OpenAlex.
- Tooth loss and infrequent brushing significantly elevate gastric cancer risk: an updated systematic review and meta-analysis with heterogeneity exploration.Frontiers in medicine · 2026Pooled it
- Association of Proton Pump Inhibitor Use With Gastric Cancer in Regions With High Prevalence of Gastric Cancer: Systematic Review and Meta-analysis.Journal of neurogastroenterology and motility · 2025Pooled it
- Novel endoscopic techniques for the diagnosis of gastricFrontiers in microbiology · 2024Pooled it
- Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial.Nature medicine · 2024Trial
- Altered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy forFrontiers in cellular and infection microbiology · 2022Trial
- Application of Visual Gene Clip-Based Tailored Therapy for the Eradication ofBioMed research international · 2021Trial
- Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.BMC pharmacology & toxicology · 2020Trial
- Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment forGut and liver · 2019Trial
- Effects ofBMJ (Clinical research ed.) · 2019Trial
- Synergistic effect of gastric microbiome and host genetic factor predispose to gastric cancer.Journal of translational medicine · 2026Article
- The prevalence of gastric intestinal metaplasia in the Saudi population: a single-tertiary center retrospective study.Journal of gastrointestinal oncology · 2026Article
- Review
- Vonoprazan-based bismuth quadruple therapy for first-line Helicobacter pylori eradication: A real-world, retrospective study.Medicine · 2026Article
- Risk ofGastro hep advances · 2026Article
- Beyond Incidence and Mortality: Socioeconomic Mediation of Gastric Cancer Disparities in the United States, 1990-2021.Annals of global health · 2026Article
- Gastric Cancer after <italic>Helicobacter pylori</italic> Eradication: Characteristics, Diagnosis, and Management.Digestion · 2025Review
- Elastic Cytomatrix Dynamics Influences Metabolic Rate and Tumor Microenvironment Formation.Cancers · 2025Review
- The Gastric Microbiome Communities and Endoscopic Mucosal Morphologies Associated with Premalignant Conditions.Microorganisms · 2025Article
- Role of physical exercise, vagal nerve stimulation, and vagotomy in inflammatory bowel disease.World journal of gastroenterology · 2025Review
- Hypermethylation-mediated HNF4A silencing by Helicobacter pylori infection drives gastric cancer by disrupting epithelial cell polarity and activating EMT signaling.Cell death & disease · 2025Article
161 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Helicobacter pylori infection contributes to the development of diverse gastric and extragastric diseases. The infection is necessary but not sufficient for the development of gastric adenocarcinoma. Its eradication would eliminate a major worldwide cause of cancer death, therefore there is much interest in identifying how, if, and when this can be accomplished. There are several mechanisms by which H pylori contributes to the development of gastric cancer. Gastric adenocarcinoma is one of many cancers associated with inflammation, which is induced by H pylori infection, yet the bacteria also cause genetic and epigenetic changes that lead to genetic instability in gastric epithelial cells. H pylori eradication reduces both. However, many factors must be considered in determining whether treating this bacterial infection will prevent cancer or only reduce its risk-these must be considered in designing reliable and effective eradication therapies. Furthermore, H pylori infection has been proposed to provide some benefits, such as reducing the risks of obesity or childhood asthma. When tested, these hypotheses have not been confirmed and are therefore most likely false.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.